摘要
目的探讨氟哌噻吨美利曲辛和盐酸帕罗西汀治疗对乳腺癌患者化疗后焦虑抑郁情绪的变化及对患者生活质量影响的比较研究。方法病例选自2012年11月~2014年1月黄石市中心医院普爱院区收治的化疗期乳腺癌患者135例,采用随机数字法分为观察组（n=68）和对照组（n=67）,对照组采用盐酸帕罗西汀治疗,观察组采用氟哌噻吨美利曲辛进行治疗,2个疗程后对比观察2组患者焦虑抑郁情况及对患者生活质量的影响。结果 2组治疗后HAMD、HAMA评分较治疗前均显著降低（P〈0.05）;治疗后,观察组HAMD、HAMA评分显著低于对照组（P〈0.05）。治疗后,观察组WHOQOL-BREF量表中健康状况主观感觉、生理领域、心理领域得分水平较治疗前均显著升高（P〈0.05）,而生存质量主观感觉、社会关系领域和环境领域与治疗前比较差异无统计学意义;治疗后,对照组仅健康状况主观感觉水平较治疗前显著升高（P〈0.05）;观察组的健康状况主观感觉、生理领域、心理领域得分与对照组比较均显著降低（P〈0.05）。观察组总不良反应发生5例（7.35%）明显低于对照组的24例（35.82%）（χ2=16.22,P〈0.05）。结论氟哌噻吨美利曲辛可以有效控制乳腺癌患者化疗后焦虑抑郁的不良情绪,使患者生活质量显著提高,效果优于盐酸帕罗西汀。
Objective To investigate the clinical effects and the quality of life of flupentixol-melitracen or paroxetine hydrochloride in treatment of the breast cancer patients with anxiety and depression after chemotherapy. Methods 135 breast cancer patients with anxiety and depression after chemotherapy were selected from November 2012 to January 2014 in the hospital. They were randomly divided into the treatment group（ n = 68） and control group（ n = 67）. The control group were treated by paroxetine hydrochloride treatment,and the treatment group were treated by flupentixolmelitracen. The anxiety,depression and its impact on quality of life of patients were observed between two groups. Results After treatment,the HAMD score and HAMA score decreased significantly in two groups（ P〈0. 05）,HAMD score and HAMA score in treatment group after treatment significantly decreased compared with control group（ P〈0. 05）. After treatment,the WHOQOL-BREF score of mental health status scale of subjective feeling,the physiological domain,domain score levels in treatment group significantly increased（ P〈0. 05）,however,the quality of life of subjective feeling,social relationship and environment domains showed no significant difference. Compared with pre-treatment,only the health status of subjective feeling levels in control group post-treatment significantly increased（ P〈0. 05）. The mental health status scale of subjective feeling,the physiological domain,domain score levels in treatment group significantly decreased compared with control group（ P〈0. 05）. The adverse reactions of treatment group were 5 cases（ 7. 35%）,which was significantly lower than 24 cases（ 35. 82%） of control group（ χ2= 16. 22,P〈0. 05）. Conclusion Flupentixol-melitracen combined with paroxetine hydrochloride has an obvious clinical effect in treatment of anxiety and depression in patients with breast cancer after chemotherapy. It could effectively control their anxiety and depression,and improve the quality of life of patients. It is worthy of clinical popularization and application.
出处
《中国生化药物杂志》
CAS
2015年第9期67-69,72,共4页
Chinese Journal of Biochemical Pharmaceutics
基金
国家自然基金青年科学基金项目(81502700)
关键词
氟哌噻吨美利曲辛
盐酸帕罗西汀
乳腺癌
焦虑
抑郁
生活质量
flupentixol-melitracen
paroxetine hydrochloride
breast cancer
anxiety
depression
quality of life
